Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients	ALK-positive Non-small Cell Lung Cancer; Real World Study	Recruiting	Not stated	2024-04-12		NCT06361589

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sichuan Cancer Hospital and Research Institute	64

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
SiChuan Cancer Hospital	Chengdu	China	6

Clinical trials